| 2026-12 (month only) | viloxazine | Knight Therapeutics, M8 Pharmaceuticals, Supernus Pharmaceuticals | Attention Deficit Hyperactivity Disorder | Phase 3 | NCT02736656 |
| 2026-12 (month only) | Docetaxel | Sanofi | Prostate Cancer | Phase 2/3 | NCT03258320 |
| 2026-12 (month only) | Methotrexate | | Cardiac Sarcoidosis, Sarcoidosis | Phase 3 | NCT03593759 |
| 2026-12 (month only) | Ralinepag | United Therapeutics | Pulmonary Arterial Hypertension | Phase 3 | NCT03683186 |
| 2026-12 (month only) | Cetuximab, Nivolumab, Binimetinib, Encorafenib, Pertuzumab | Eli Lilly, Merck KGaA, Bristol-Myers Squibb | Metastatic Colon Cancer, Stage III Colon Cancer | Phase 3 | NCT03803553 |
| 2026-12 (month only) | Palbociclib | Pfizer | HR+/HER2- Metastatic Breast Cancer, Breast Cancer | Phase 3 | NCT03820830 |
| 2026-12 (month only) | Niraparib, Capivasertib, Docetaxel | GlaxoSmithKline, Zai Lab, Astex Pharmaceuticals, Inc. | Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer | Phase 3 | NCT03903835 |
| 2026-12 (month only) | Durvalumab | AstraZeneca | Oropharyngeal Cancer | Phase 3 | NCT04116047 |
| 2026-12 (month only) | Camrelizumab, Apatinib | Elevar Therapeutics, Inc., Jiangsu Hengrui Pharmaceuticals, Advenchen Laboratories | Gastric Cancer | Phase 2/3 | NCT04208347 |
| 2026-12 (month only) | apremilast | Amgen | Recurrent Aphtous Stomatitis | Phase 3 | NCT04227314 |
| 2026-12 (month only) | Penpulimab | Akeso, Chia Tai Tianqing Pharmaceutical Group | Hepatocellular Carcinoma | Phase 3 | NCT04344158 |
| 2026-12 (month only) | Selinexor, Rituximab, Dexamethasone | A. Menarini, Antengene Corporation Limited, FORUS Therapeutics Inc. | Diffuse Large B-Cell Lymphoma | Phase 2/3 | NCT04442022 |
| 2026-12 (month only) | Durvalumab, Tremelimumab, pemetrexed | AstraZeneca, MedImmune LLC, Eli Lilly | Non-Small Cell Lung Cancer | Phase 3 | NCT04585490 |
| 2026-12 (month only) | Sacituzumab Govitecan | Gilead Sciences | HR+/HER2- Metastatic Breast Cancer, Breast Cancer | Phase 3 | NCT04639986 |
| 2026-12 (month only) | Surabgene lomparvovec | AbbVie, REGENXBIO Inc. | Age-Related Macular Degeneration | Phase 2/3 | NCT04704921 |
| 2026-12 (month only) | Furmonertinib | Allist Pharmaceuticals, ArriVent BioPharma | Non-small Cell Lung Carcinoma | Phase 3 | NCT04853342 |
| 2026-12 (month only) | Rinvecalinase alfa | DiaMedica Therapeutics | Acute Ischemic Stroke | Phase 2/3 | NCT05065216 |
| 2026-12 (month only) | Bevacizumab, Olvimulogene nanivacirepvec | Roche, Genelux Corporation, Newsoara HYK Biopharmaceuticals Co., Ltd. | Ovarian Cancer | Phase 3 | NCT05281471 |
| 2026-12 (month only) | Toripalimab | Coherus BioSciences, Inc., Shanghai Junshi Bioscience | Nasopharyngeal Carcinoma | Phase 3 | NCT05340491 |
| 2026-12 (month only) | Donidalorsen | Ionis Pharmaceuticals, Otsuka Holdings, Theratechnologies | Hereditary Angioedema | Phase 3 | NCT05392114 |
| 2026-12 (month only) | Masupirdine | Suven Life Sciences | Alzheimer's Disease | Phase 3 | NCT05397639 |
| 2026-12 (month only) | Canagliflozin | Daiichi Sankyo, Johnson & Johnson, Tanabe Pharma Corporation | Type 2 Diabetes | Phase 2/3 | NCT05427084 |
| 2026-12 (month only) | Actinium (225Ac) oxodotreotide | Bristol-Myers Squibb | GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET | Phase 3 | NCT05477576 |
| 2026-12 (month only) | Resmetirom | Madrigal Pharmaceuticals | MASH / NASH | Phase 3 | NCT05500222 |
| 2026-12 (month only) | Bevacizumab | Roche | Non-Small Cell Lung Cancer | Phase 3 | NCT05654454 |
| 2026-12 (month only) | Pegtarazimod | ReAlta Life Sciences | Hypoxic-Ischemic Encephalopathy | Phase 2/3 | NCT05778188 |
| 2026-12 (month only) | Tamoxifen (Soltamox), Anastrozole, Letrozole, Culmerciclib | Mayne Pharma, Rosemont Pharmaceuticals, ANI Pharmaceuticals, Inc. | Breast Cancer | Phase 3 | NCT05780567 |
| 2026-12 (month only) | Sintilimab | Innovent Biologics | Gastric Cancer | Phase 3 | NCT05918094 |
| 2026-12 (month only) | Tinengotinib | TransThera Sciences (Nanjing), Inc. | Cholangiocarcinoma | Phase 3 | NCT05948475 |
| 2026-12 (month only) | Opakalim | Biohaven | Epilepsy, Focal Onset Seizures | Phase 2/3 | NCT06132893 |
| 2026-12 (month only) | Tislelizumab | BeOne Medicines | Nasopharyngeal Carcinoma | Phase 3 | NCT06177301 |
| 2026-12 (month only) | Cadonilimab, Disitamab Vedotin | Akeso, Pfizer, RemeGen Co., Ltd. | Gastric Cancer | Phase 2/3 | NCT06221748 |
| 2026-12 (month only) | Seralutinib | Gossamer Bio | Pulmonary Arterial Hypertension | Phase 3 | NCT06274801 |
| 2026-12 (month only) | Izalontamab brengitecan, Docetaxel | Bristol-Myers Squibb, Sichuan Baili Pharmaceutical, Sanofi | Non-Small Cell Lung Cancer | Phase 3 | NCT06382129 |
| 2026-12 (month only) | Solriamfetol | Axsome Therapeutics, Pharmanovia, SK Biopharmaceuticals Co., Ltd. | Binge-Eating Disorder | Phase 3 | NCT06413433 |
| 2026-12 (month only) | lutikizumab | AbbVie | Hidradenitis Suppurativa | Phase 3 | NCT06468228 |
| 2026-12 (month only) | Lumateperone | Intra-Cellular Therapies, Johnson & Johnson | Schizophrenia | Phase 3 | NCT06482554 |
| 2026-12 (month only) | Izalontamab brengitecan | Bristol-Myers Squibb, Sichuan Baili Pharmaceutical | Small Cell Lung Cancer | Phase 3 | NCT06500026 |
| 2026-12 (month only) | Solriamfetol | Axsome Therapeutics, Pharmanovia, SK Biopharmaceuticals Co., Ltd. | Excessive Sleepiness, Shift-work Disorder | Phase 3 | NCT06568367 |
| 2026-12 (month only) | Ruzaltatug rezetecan | Jiangsu Hengrui Pharmaceuticals | Non-Small Cell Lung Cancer | Phase 3 | NCT06671379 |
| 2026-12 (month only) | Pembrolizumab, Sacituzumab Tirumotecan | Merck & Co., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Non-Small Cell Lung Cancer | Phase 3 | NCT06711900 |
| 2026-12 (month only) | Crofelemer | Future Pak, LLC, Jaguar Health, Napo Pharmaceuticals | Microvillus Inclusion Disease, Congenital Disorders, Rare Diseases | Phase 2/3 | NCT06721871 |
| 2026-12 (month only) | Dolutegravir | Shionogi, ViiV Healthcare | HIV | Phase 3 | NCT06747507 |
| 2026-12 (month only) | pemetrexed | Eli Lilly | Non-Small Cell Lung Cancer | Phase 3 | NCT06754644 |
| 2026-12 (month only) | Ivonescimab | Akeso, Summit Therapeutics | Triple-Negative Breast Cancer (TNBC) | Phase 3 | NCT06767527 |
| 2026-12 (month only) | upadacitinib, Pirfenidone (Esbriet) | AbbVie, Legacy Pharma Inc. SEZC, Roche | Long COVID | Phase 3 | NCT06928272 |
| 2026-12 (month only) | ribupatide | Jiangsu Hengrui Pharmaceuticals, Kailera Therapeutics | Obesity | Phase 3 | NCT06974851 |
| 2026-12 (month only) | ribupatide | Jiangsu Hengrui Pharmaceuticals, Kailera Therapeutics | Obesity | Phase 3 | NCT06994650 |
| 2026-12 (month only) | Relutrigine | Praxis Precision Medicines, Inc. | Epilepsy, Developmental and Epileptic Encephalopathies | Phase 3 | NCT07010471 |
| 2026-12 (month only) | Elsunersen | Ionis Pharmaceuticals, Praxis Precision Medicines, Inc. | Epilepsy | Phase 3 | NCT07019922 |
| 2026-12 (month only) | Semaglutide (Ozempic) | Novo Nordisk | Type 2 Diabetes | Phase 3 | NCT07059377 |
| 2026-12 (month only) | metformin, Alogliptin, Empagliflozin | Takeda Pharmaceutical Company, Teijin, Boehringer Ingelheim | Type 2 Diabetes | Phase 3 | NCT07093476 |
| 2026-12 (month only) | Tobevibart (VIR-3434) | Brii Biosciences, Norgine, Vir Biotechnology | Chronic Hepatitis Delta | Phase 3 | NCT07128550 |
| 2026-12 (month only) | difamilast | Acrotech Biopharma, Otsuka Holdings | Atopic Dermatitis | Phase 3 | NCT07173478 |
| 2026-12 (month only) | stapokibart | Aeira Pte. Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Keymed Biosciences | Seasonal Allergic Rhinitis (SAR) | Phase 3 | NCT07678931 |
| 2026-12 (month only) | SHR-1819 | Jiangsu Hengrui Pharmaceuticals | Seasonal Allergic Rhinitis | Phase 3 | NCT07688772 |
| 2026-12-01 | Pyrotinib, Epirubicin | Dr. Reddy's Laboratories, HLB Life Science, Jiangsu Hengrui Pharmaceuticals | Breast Cancer | Phase 2/3 | NCT04290793 |
| 2026-12-01 | SPH4336 | Shanghai Pharmaceuticals Holding | HR+/HER2- Metastatic Breast Cancer | Phase 2/3 | NCT05860465 |
| 2026-12-01 | Tislelizumab | BeOne Medicines | Locally Advanced Rectal Carcinoma | Phase 2/3 | NCT06312982 |
| 2026-12-01 | Felzartamab | Biogen | Antibody-mediated Rejection | Phase 3 | NCT06685757 |
| 2026-12-01 | Maraviroc | ViiV Healthcare | Long COVID | Phase 2/3 | NCT06974084 |
| 2026-12-01 | Cetuximab, Pembrolizumab | Eli Lilly, Merck KGaA, Merck & Co. | Head and Neck Squamous Cell Carcinoma | Phase 3 | NCT06998069 |
| 2026-12-01 | RAY1225 | Guangdong Raynovent Biotech, Qilu Pharmaceutical | Type 2 Diabetes | Phase 3 | NCT07139535 |
| 2026-12-01 | RAY1225 | Guangdong Raynovent Biotech, Qilu Pharmaceutical | Type 2 Diabetes | Phase 3 | NCT07139548 |
| 2026-12-01 | tradipitant | Vanda Pharmaceuticals | Nausea and Vomiting, Obesity | Phase 3 | NCT07446439 |
| 2026-12-01 | Venetoclax | AbbVie, Roche | Acute Myeloid Leukemia | Phase 3 | NCT07712848 |
| 2026-12-02 | PF-06651600 | Pfizer | Severe Alopecia Areata | Phase 3 | NCT07029711 |
| 2026-12-04 | Anakinra | Swedish Orphan Biovitrum AB (publ) | FMF | Phase 3 | NCT06336733 |
| 2026-12-04 | PF-07307405 | Pfizer | Lyme Disease | Phase 3 | NCT07500506 |
| 2026-12-06 | Dexamethasone | | Nausea and Vomiting Caused by Chemotherapy | Phase 3 | NCT07716176 |
| 2026-12-06 | Dexamethasone | | Nausea and Vomiting Caused by Trastuzumab Deruxtecan | Phase 3 | NCT07716189 |
| 2026-12-06 | Dexamethasone | | Nausea and Vomiting Caused by Chemotherapy | Phase 3 | NCT07716228 |
| 2026-12-07 | Eculizumab | Alexion Pharmaceuticals, Inc. (subsidiary of AstraZeneca) | NMOSD, Neuromyelitis Optica Spectrum Disorders | Phase 3 | NCT06724809 |
| 2026-12-08 | Milvexian | Bristol-Myers Squibb, Johnson & Johnson | Atrial Fibrillation | Phase 3 | NCT05757869 |
| 2026-12-09 | Xanomeline/trospium chloride | Bristol-Myers Squibb, Zai Lab | Alzheimer's Disease | Phase 3 | NCT06126224 |
| 2026-12-10 | Zongertinib | Boehringer Ingelheim | Non-Small Cell Lung Cancer | Phase 3 | NCT06151574 |
| 2026-12-12 | Osimertinib, CPO301 | AstraZeneca, Conjupro Biotherapeutics, Inc. | Non-Small Cell Lung Cancer | Phase 3 | NCT07376382 |
| 2026-12-13 | ivarmacitinib | Jiangsu Hengrui Pharmaceuticals, Reistone Biopharma | Psoriatic Arthritis | Phase 3 | NCT04957550 |
| 2026-12-13 | crisaborole | Pfizer | Psoriasis, Psoriasis Genital | Phase 3 | NCT07892339 |
| 2026-12-14 | Abp 234 | Amgen | Non-Small Cell Lung Cancer | Phase 3 | NCT06430866 |
| 2026-12-15 | Atezolizumab, Pertuzumab | Chugai Pharma, Roche | Breast Cancer | Phase 3 | NCT03595592 |
| 2026-12-15 | Cariprazine (Vraylar) | AbbVie, Gedeon Richter, Tanabe Pharma Corporation | Schizophrenia | Phase 3 | NCT03817502 |
| 2026-12-15 | Nivolumab, Zanzalintinib | Bristol-Myers Squibb, Ono Pharmaceutical, Exelixis | Renal Cell Carcinoma | Phase 3 | NCT05678673 |
| 2026-12-15 | N-acetylcysteine | Apotex Inc., Phebra Pty Ltd | Psychosis | Phase 3 | NCT05796401 |
| 2026-12-15 | Dexamethasone | | Hospital Acquired Pneumonia | Phase 3 | NCT06269900 |
| 2026-12-15 | Gefurulimab | AstraZeneca | Generalized Myasthenia Gravis | Phase 3 | NCT06607627 |
| 2026-12-15 | Temozolomide | Merck & Co. | Neuroblastoma (NB), Ganglioneuroblastoma | Phase 3 | NCT07375563 |
| 2026-12-16 | Docetaxel (HB1801) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | HER2-Positive Breast Cancer | Phase 3 | NCT06747338 |
| 2026-12-17 | Elafibranor | Genfit, Ipsen | Primary Biliary Cholangitis | Phase 3 | NCT06730061 |
| 2026-12-17 | Oveporexton | Takeda Pharmaceutical Company | Narcolepsy | Phase 3 | NCT07363720 |
| 2026-12-20 | Dexamethasone | | Facial Injuries, Pain, Swelling | Phase 2/3 | NCT07853664 |
| 2026-12-21 | bimekizumab | UCB | Hidradenitis Suppurativa | Phase 3 | NCT06921850 |
| 2026-12-22 | Ixoberogene soroparvovec | Eli Lilly | Wet Age-Related Macular Degeneration | Phase 3 | NCT06856577 |
| 2026-12-22 | Suzetrigine | Vertex Pharmaceuticals | Bariatric Surgery, Cardiac Surgery With Sternotomy, Post-operative Pain | Phase 3 | NCT07539623 |
| 2026-12-23 | Benralizumab | AstraZeneca, Kyowa Kirin, MedImmune LLC | Asthma | Phase 3 | NCT05692180 |
| 2026-12-24 | Vemurafenib | Roche | Colorectal Cancer Metastatic | Phase 3 | NCT06008119 |
| 2026-12-26 | Trelagliptin | Takeda Pharmaceutical Company, Teijin | Type 2 Diabetes | Phase 3 | NCT07073768 |
| 2026-12-28 | Carfilzomib, Bortezomib, Lenalidomide, Dexamethasone | Amgen, Ono Pharmaceutical, Janssen | Multiple Myeloma | Phase 3 | NCT03729804 |
| 2026-12-28 | TH-SC01 | Jiangsu Topcel-KH Pharmaceutical | Crohn's Disease | Phase 3 | NCT06925594 |
| 2026-12-28 | Olanzapine (Zyprexa) | Cheplapharm Arzneimittel GmbH, Eli Lilly | Oncology Patients Receiving Chemotherapy, Cachexia-Anorexia Syndrome, Oncology | Phase 3 | NCT07633236 |
| 2026-12-30 | Cetrelimab | Johnson & Johnson | Bladder Cancer | Phase 3 | NCT04658862 |
| 2026-12-30 | Toripalimab | Coherus BioSciences, Inc., Shanghai Junshi Bioscience | Non-Small Cell Lung Cancer | Phase 3 | NCT04772287 |
| 2026-12-30 | Camrelizumab, Apatinib | Elevar Therapeutics, Inc., Jiangsu Hengrui Pharmaceuticals, Advenchen Laboratories | Hepatocellular Carcinoma | Phase 2/3 | NCT05062837 |
| 2026-12-30 | Sintilimab, Bevacizumab, Capecitabine | Innovent Biologics, Roche, Cheplapharm Arzneimittel GmbH | Colorectal Cancer, Metastatic Colorectal Cancer | Phase 3 | NCT05171660 |
| 2026-12-30 | Palbociclib, Vepdegestrant | Pfizer, Arvinas Inc., Rigel Pharmaceuticals | HR+/HER2- Metastatic Breast Cancer, Breast Cancer | Phase 3 | NCT05909397 |
| 2026-12-30 | TAK-921 | Takeda Pharmaceutical Company | Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 3 | NCT06238843 |
| 2026-12-30 | Seltorexant | Johnson & Johnson | Major Depressive Disorder | Phase 3 | NCT06559306 |
| 2026-12-30 | Sumecigrel | Everest Medicines (Beijing) Co., Ltd., Jiangsu Vcare Pharmaceutical Technology Co., Ltd. | Atherosclerotic Cardiovascular Disease | Phase 3 | NCT06577519 |
| 2026-12-30 | Sodium zirconium cyclosilicate | AstraZeneca | Chronic Kidney Disease | Phase 3 | NCT06578078 |
| 2026-12-30 | Anbenitamab repodatecan | Alphamab Oncology, CSPC Pharmaceutical Group | Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancers | Phase 3 | NCT06751485 |
| 2026-12-30 | Descartes-08 | Cartesian Therapeutics, Inc. | Myasthenia Gravis | Phase 3 | NCT06799247 |
| 2026-12-30 | Venetoclax | AbbVie, Roche | Acute Myeloid Leukemia | Phase 2/3 | NCT07264010 |
| 2026-12-30 | Telitacicept | RemeGen Co., Ltd., Vor Bio | Inflammatory Myopathy | Phase 2/3 | NCT07355257 |
| 2026-12-30 | Pirfenidone (Esbriet) | Legacy Pharma Inc. SEZC, Roche | Radiation-induced Lung Injury, Immune-related Pneumonia | Phase 2/3 | NCT07388680 |
| 2026-12-31 | Temozolomide | Merck & Co. | Glioma | Phase 3 | NCT00978458 |
| 2026-12-31 | Ibrutinib | AbbVie, Johnson & Johnson | Diffuse Large B-Cell Lymphoma, Graft-versus-Host Disease, Chronic Graft-versus-Host Disease, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia | Phase 3 | NCT01804686 |
| 2026-12-31 | Carfilzomib, Bortezomib, Lenalidomide, Dexamethasone | Amgen, Ono Pharmaceutical, Janssen | Multiple Myeloma | Phase 3 | NCT01863550 |
| 2026-12-31 | Gemcitabine | Eli Lilly | Hepatoblastoma, Carcinoma, Hepatocellular | Phase 3 | NCT03017326 |
| 2026-12-31 | Bevacizumab | Roche | Colorectal Cancer | Phase 3 | NCT03303495 |
| 2026-12-31 | Pembrolizumab | Merck & Co. | Merkel Cell Carcinoma | Phase 3 | NCT03712605 |
| 2026-12-31 | Toripalimab | Coherus BioSciences, Inc., Shanghai Junshi Bioscience | Hepatocellular Carcinoma | Phase 2/3 | NCT03859128 |
| 2026-12-31 | Lecanemab | Biogen, Eisai | Alzheimer's Disease | Phase 3 | NCT03887455 |
| 2026-12-31 | Migalastat | Amicus Therapeutics, BioMarin Pharmaceutical | Fabry Disease | Phase 3 | NCT04020055 |
| 2026-12-31 | Pembrolizumab | Merck & Co. | Lung Cancer | Phase 2/3 | NCT04093167 |
| 2026-12-31 | Tislelizumab, zanubrutinib | BeOne Medicines | B-cell Malignancies | Phase 3 | NCT04170283 |
| 2026-12-31 | Toripalimab | Coherus BioSciences, Inc., Shanghai Junshi Bioscience | Advanced Hepatocellular Carcinoma (HCC) | Phase 3 | NCT04523493 |
| 2026-12-31 | Dexamethasone | | Hodgkin Lymphoma, Adult | Phase 3 | NCT04638790 |
| 2026-12-31 | Fluzoparib | Jiangsu Hengrui Pharmaceuticals | Metastatic Castration-Resistant Prostate Cancer | Phase 3 | NCT04691804 |
| 2026-12-31 | Almonertinib | Glenmark Pharmaceuticals Ltd., Hansoh Pharmaceutical Group | Non-Small Cell Lung Cancer | Phase 3 | NCT04841811 |
| 2026-12-31 | Methylprednisolone | Pfizer | Opioid Use, Lumbar Spinal Stenosis, Pain, Postoperative, Pain, Back | Phase 3 | NCT05058287 |
| 2026-12-31 | Lorlatinib, Avelumab, Axitinib, pemetrexed, Talazoparib | Pfizer, Merck KGaA, Eli Lilly | Non-Small Cell Lung Cancer, Urothelial Carcinoma | Phase 3 | NCT05059522 |
| 2026-12-31 | Toripalimab, Disitamab Vedotin | Coherus BioSciences, Inc., Shanghai Junshi Bioscience, Pfizer | Urothelial Carcinoma | Phase 3 | NCT05302284 |
| 2026-12-31 | Durvalumab | AstraZeneca | Cancer | Phase 3 | NCT05303532 |
| 2026-12-31 | Empagliflozin | Boehringer Ingelheim, Eli Lilly | Heart Failure | Phase 3 | NCT05392764 |
| 2026-12-31 | Trastuzumab rezetecan | Glenmark Pharmaceuticals Ltd., Jiangsu Hengrui Pharmaceuticals | Breast Cancer | Phase 3 | NCT05424835 |
| 2026-12-31 | Methotrexate | | T-cell Lymphoblastic Lymphoma | Phase 3 | NCT05681260 |
| 2026-12-31 | Gemcitabine | Eli Lilly | Cervical Cancer, Cervix Cancer, Cervix Neoplasm | Phase 3 | NCT05764044 |
| 2026-12-31 | S-1, Docetaxel | Nordic Group B.V., Taiho Pharmaceutical, Sanofi | Locally Advanced Gastric Adenocarcinoma, Chemotherapy Effect | Phase 3 | NCT05813015 |
| 2026-12-31 | Tislelizumab | BeOne Medicines | Advanced Cholangiocarcinoma | Phase 3 | NCT05823311 |
| 2026-12-31 | Sacituzumab Tirumotecan | Merck & Co., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | HR+/HER2- Metastatic Breast Cancer, Breast Cancer | Phase 3 | NCT06081959 |
| 2026-12-31 | Lisaftoclax | Ascentage Pharma Group Inc. | CLL/SLL | Phase 3 | NCT06104566 |
| 2026-12-31 | Cetuximab | Eli Lilly, Merck KGaA | Metastatic Colorectal Cancer | Phase 3 | NCT06226857 |
| 2026-12-31 | Chidamide | Chipscreen Biosciences, GNT Biotech & Medicals, HUYABIO International, LLC. | Extranodal Natural Killer T Cell Lymphoma | Phase 3 | NCT06255795 |
| 2026-12-31 | Bevacizumab, Serplulimab | Roche, Abbott, Accord Healthcare | Colorectal Cancer | Phase 2/3 | NCT06280495 |
| 2026-12-31 | Dapagliflozin | AstraZeneca, Ono Pharmaceutical | Heart Failure | Phase 3 | NCT06304857 |
| 2026-12-31 | Nab-paclitaxel, Temozolomide | Bristol-Myers Squibb, Merck & Co. | Glioma | Phase 3 | NCT06330337 |
| 2026-12-31 | Azacitidine | Bristol-Myers Squibb | Acute Myeloid Leukemia | Phase 3 | NCT06345365 |
| 2026-12-31 | Rademikibart | Connect Biopharma, Simcere Pharmaceutical | Asthma | Phase 3 | NCT06488755 |
| 2026-12-31 | Vicadrostat | Boehringer Ingelheim | Chronic Kidney Disease | Phase 3 | NCT06531824 |
| 2026-12-31 | Camrelizumab, Capecitabine | Elevar Therapeutics, Inc., Jiangsu Hengrui Pharmaceuticals, Cheplapharm Arzneimittel GmbH | Triple-negative Breast Cancer | Phase 3 | NCT06533384 |
| 2026-12-31 | Bexicaserin | H. Lundbeck | Epilepsy | Phase 3 | NCT06660394 |
| 2026-12-31 | Furmonertinib | Allist Pharmaceuticals, ArriVent BioPharma | Non-Small Cell Lung Cancer | Phase 3 | NCT06674343 |
| 2026-12-31 | Icosapent Ethyl | Amarin Corporation, Recordati | Inflammation, Community Acquired Pneumonia (CAP), Inflammation Plaque, Atherosclerotic | Phase 3 | NCT06710080 |
| 2026-12-31 | SC0062 | BioCity Biopharmaceutics | Chronic Kidney Disease | Phase 3 | NCT06819826 |
| 2026-12-31 | mazdutide | Eli Lilly, Innovent Biologics | Obesity | Phase 3 | NCT06884293 |
| 2026-12-31 | Dapagliflozin | AstraZeneca, Ono Pharmaceutical | Pediatric Hereditary Kidney Diseases | Phase 3 | NCT06890143 |
| 2026-12-31 | Pembrolizumab | Merck & Co. | Esophageal Squamous Cell Carcinoma | Phase 2/3 | NCT06907602 |
| 2026-12-31 | Tislelizumab | BeOne Medicines | Gastric Cancer | Phase 3 | NCT06939439 |
| 2026-12-31 | Venetoclax | AbbVie, Roche | Acute Myeloid Leukemia | Phase 3 | NCT06990321 |
| 2026-12-31 | upadacitinib | AbbVie | Crohn's Disease | Phase 3 | NCT07149467 |
| 2026-12-31 | Pembrolizumab | Merck & Co. | Non-Small Cell Lung Cancer | Phase 3 | NCT07162883 |
| 2026-12-31 | Telitacicept | RemeGen Co., Ltd., Vor Bio | Myasthenia Gravis, Ocular | Phase 3 | NCT07249632 |
| 2026-12-31 | N-acetylcysteine | Apotex Inc., Phebra Pty Ltd | Thrombotic Microangiopathy | Phase 2/3 | NCT07279610 |
| 2026-12-31 | Azvudine | Henan Genuine Biotech | Chronic Hepatitis B, Azvudine | Phase 3 | NCT07307586 |
| 2026-12-31 | Eculizumab | Alexion Pharmaceuticals, Inc. (subsidiary of AstraZeneca) | Neuromyelitis Optica Spectrum Disorders (NMOSD) | Phase 3 | NCT07420296 |
| 2026-12-31 | Venetoclax, Azacitidine | AbbVie, Roche, Bristol-Myers Squibb | Acute Myeloid Leukemia | Phase 3 | NCT07486479 |
| 2026-12-31 | HRS-9190 | Jiangsu Hengrui Pharmaceuticals | Adult Participants Requiring Tracheal Intubation Under General Anesthesia for Elective Surgery | Phase 3 | NCT07733245 |
| 2026-12-31 | HRS-9190 | Jiangsu Hengrui Pharmaceuticals | Neuromuscular Blockade | Phase 3 | NCT07746726 |